2 No-Brainer Stocks to Buy Now With $250 Before They Soar in 2025, According to Wall Street

As we approach 2025, investors are looking for the next big opportunities in the stock market. Two stocks that have caught the attention of Wall Street analysts are Cellectar Biosciences Inc (NASDAQ: CLRB) and Moderna (NASDAQ: MRNA). Both stocks have the potential to soar in the coming years, making them attractive investments for those with a long-term perspective.

Cellectar Biosciences Inc (NASDAQ: CLRB) is a late-stage clinical biopharmaceutical company that has a 'oderate buy' consensus rating on the stock analysis platform TipRanks. The average forecast indicates a 2661.34% rally for CLRB in the coming 52 weeks. Although the stock has done little other than decline in 2024, analysts are optimistic about its potential for growth. The bullish prediction is based on no more than three analyst ratings, which may indicate a higher risk but also a higher potential reward.

Moderna (NASDAQ: MRNA) is a pharmaceutical and biotechnology giant that has a 'hold' average rating, but analysts remain mostly optimistic about the company's potential to recover and grow. The stock is expected to soar more than 54.73% in the coming 12 months, according to TipRanks. Although the stock has lost much significance since the COVID-19 pandemic, analysts believe that the company's profit will rise 24% this year and 4% in 2025. The company's services segment, which includes payment processing, streaming media, and other features, has become an increasingly important source of revenue and growth.

Investors who are looking to buy these stocks should consider the risks and uncertainties associated with each company's specific situation. While both stocks have the potential for growth in the near future, it's essential to conduct thorough research and consider your risk tolerance before making any investment decisions.

In conclusion, Cellectar Biosciences Inc (NASDAQ: CLRB) and Moderna (NASDAQ: MRNA) are two no-brainer stocks to buy now with $250 before they soar in 2025, according to Wall Street. Both stocks have the potential for significant growth in the coming years, making them attractive investments for those with a long-term perspective. However, investors should be aware of the risks and uncertainties associated with each company and conduct thorough research before making any investment decisions.